Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
A Ntalianis, C Chrysohoou, G Giannakoulas… - Heart Failure …, 2022 - Springer
The short-term mortality and rehospitalization rates after admission for acute heart failure
(AHF) remain high, despite the high level of adherence to contemporary practice guidelines …
(AHF) remain high, despite the high level of adherence to contemporary practice guidelines …
Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction
M Fudim, S Sayeed, H Xu, RA Matsouaka… - Circulation: Heart …, 2020 - Am Heart Assoc
Background: In PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect
on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital …
on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital …
Clinical effectiveness of sacubitril/valsartan among patients hospitalized for heart failure with reduced ejection fraction
SJ Greene, S Choi, SJ Lippmann… - Journal of the …, 2021 - Am Heart Assoc
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart
failure with reduced ejection fraction (HFrEF). However, the effectiveness of …
failure with reduced ejection fraction (HFrEF). However, the effectiveness of …
Acute hemodynamic effects of sacubitril-valsartan in heart failure patients receiving intravenous vasodilator and inotropic therapy
T Martyn, KD Faulkenberg, CL Albert, ZJ Il'giovine… - Journal of Cardiac …, 2021 - Elsevier
Background Prior study has demonstrated that transitioning patients in acutely
decompensated heart failure with a low cardiac output directly from intravenous (iv) …
decompensated heart failure with a low cardiac output directly from intravenous (iv) …
[HTML][HTML] Initiation of angiotensin receptor-neprilysin inhibitor in heart failure with low cardiac output
T Martyn, KD Faulkenberg, DM Yaranov… - Journal of the American …, 2019 - jacc.org
The benefits of angiotensin receptor-neprilysin inhibitor (ARNI) in patients with heart failure
with reduced ejection fraction (HFrEF) are well established (1). The majority of patients with …
with reduced ejection fraction (HFrEF) are well established (1). The majority of patients with …
Molecular profiling of Neprilysin expression and its interactions with SARS-CoV-2 spike proteins to develop evidence base pharmacological approaches for …
A Kumar - 2021 - researchsquare.com
Neprilysin due to its peptidase activity is involved in several physiological and pathological
processes. Recently our group has reported the association of neprilysin with angiotensin …
processes. Recently our group has reported the association of neprilysin with angiotensin …
[引用][C] Möglichkeiten der Therapieoptimierung von Patienten mit Herzinsuffizienz im Krankenhaus
A Staudt